Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years. 2.

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. The company has also worked hard to diversify its pipeline. The stock is worth the premium. And that's before we get into ...

Eli Lilly is worth a premium considering the strength of its financial results, even if the stock is somewhat volatile in the short term. The company's work in weight management, diabetes, and ...

Eli Lilly and Company (NYSE:LLY) is advancing its neuroscience portfolio by acquiring SiteOne Therapeutics in a deal valued at up to $1 billion, reinforcing its focus on non-opioid pain therapies ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn.

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition by the world’s most valuable drugmaker as it seeks to boost its pipeline of ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...

Eli Lilly & Co. agreed to buy Verve Therapeutics Inc., a US biotech that’s seeking to use gene editing to prevent clogged arteries, for as much as $1.3 billion.